theMednetRegister
  • Community
    • Overview
    • Experts
    • Editors
    • Fellows
    • Code of conduct
    • AI Guidelines for Physicians
  • Company
    • About Us
    • FAQs
    • Privacy Policy
    • Terms of Use
    • Careers
    • Programs
  • News
    • News Releases
    • Press Coverage
    • Publications
    • Blog
  • Contact Us
  • Sign in

Hematology

Multispecialty Spotlight   

Multi-specialty Spotlight

Questions discussed in this category


Should testing for genetic causes of HLH be performed in all patients with MAS or secondary HLH regardless of the patient's age?
2 Answers available

How do you approach dosing of anakinra in MAS?
1 Answer available

How do you approach diagnosis and treatment of HLH/MAS following CAR T-cell therapy?
How is this entity distinct from other secondary HLH entities? 
2 Answers available

What is your approach to treatment of infection-triggered HLH that does not respond to treatment of the underlying infection?
2 Answers available

In the setting of secondary HLH associated with initial diagnosis of lymphoma, would you adjust steroid dose and type to account for differences in HLH and lymphoma treatment protocols?
1 Answer available

What are the best labs to trend improvement in HLH?
1 Answer available
146701622516186162171619515429


Papers discussed in this category


Pediatric blood & cancer, 2011-01
Rate of decline of ferritin in patients with hemophagocytic lymphohistiocytosis as a prognostic variable for mortality.

Ther Adv Musculoskelet Dis, 2020 Nov 24
Efficacy of high-dose anakinra in refractory macrophage activation syndrome in adult-onset Still's disease: when dosage matters in overcoming secondary therapy resistance.

Related Topics in Hematology

  • Lung Cancer
  • Breast Cancer
  • Head and Neck Cancers
  • Hematologic Malignancies
  • Radiation Oncology
  • Gynecologic Oncology
  • Palliation
  • Neuro-Oncology
  • Gastrointestinal Cancers
  • Genitourinary Cancers

Copyright © 2025 theMednet
All Rights Reserved.